3,524 Shares in Revvity Inc. (NYSE:RVTY) Acquired by Kentucky Retirement Systems Insurance Trust Fund

Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in Revvity Inc. (NYSE:RVTY) in the first quarter, Holdings Channel reports. The fund acquired 3,524 shares of the company’s stock, valued at approximately $373,000.

A number of other large investors also recently modified their holdings of RVTY. Assetmark Inc. grew its holdings in Revvity by 3,700.0% during the fourth quarter. Assetmark Inc. now owns 266 shares of the company’s stock worth $30,000 after buying an additional 259 shares in the last quarter. Optiver Holding B.V. purchased a new position in Revvity in the fourth quarter worth $33,000. Quarry LP grew its position in Revvity by 45.7% during the fourth quarter. Quarry LP now owns 303 shares of the company’s stock valued at $34,000 after buying an additional 95 shares during the period. Millstone Evans Group LLC bought a new stake in shares of Revvity in the 4th quarter worth approximately $38,000. Finally, Vermillion Wealth Management Inc. bought a new position in shares of Revvity during the 4th quarter worth $41,000. 86.65% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

RVTY has been the topic of several analyst reports. Wall Street Zen cut Revvity from a “buy” rating to a “hold” rating in a research report on Saturday, May 24th. JPMorgan Chase & Co. lowered their price objective on shares of Revvity from $120.00 to $100.00 and set a “neutral” rating for the company in a report on Tuesday, April 29th. The Goldman Sachs Group lowered their price objective on shares of Revvity from $140.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, April 29th. Robert W. Baird lowered their price objective on Revvity from $127.00 to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, April 29th. Finally, UBS Group raised shares of Revvity from a “neutral” rating to a “buy” rating and cut their price objective for the company from $145.00 to $115.00 in a research report on Thursday, May 1st. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Revvity currently has a consensus rating of “Moderate Buy” and a consensus price target of $125.64.

Revvity Stock Performance

RVTY opened at $97.90 on Thursday. The company has a fifty day moving average of $93.10 and a 200 day moving average of $105.73. Revvity Inc. has a fifty-two week low of $87.70 and a fifty-two week high of $129.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.99 and a current ratio of 3.58. The stock has a market capitalization of $11.54 billion, a price-to-earnings ratio of 41.66, a PEG ratio of 2.35 and a beta of 0.97.

Revvity (NYSE:RVTY) last released its earnings results on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.05. The business had revenue of $664.76 million for the quarter, compared to analyst estimates of $662.30 million. Revvity had a return on equity of 7.73% and a net margin of 10.35%. The business’s revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.98 earnings per share. As a group, sell-side analysts forecast that Revvity Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be issued a dividend of $0.07 per share. The ex-dividend date is Friday, July 18th. This represents a $0.28 annualized dividend and a dividend yield of 0.29%. Revvity’s dividend payout ratio (DPR) is currently 11.91%.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.